Liquidia Technologies Inc (LQDA)
NASDAQ:LQDA
LQDA Stock Chart & Stats
$36.77
<$0.01(<0.01%)
At close: 4:00 PM EST
$36.77
<$0.01(<0.01%)
Day’s Range― - ―
52-Week Range$11.26 - $46.67
Previous CloseN/A
Volume97.81K
Average Volume (3M)1.69M
Market Cap
$3.24B
Enterprise Value$3.25B
Total Cash (Recent Filing)$190.68M
Total Debt (Recent Filing)$197.93M
Price to Earnings (P/E)―
Beta1.68
Next Earnings
May 07, 2026EPS Estimate
0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.15
Shares Outstanding88,114,426
10 Day Avg. Volume1,140,707
30 Day Avg. Volume1,689,574
Financial Highlights & Ratios
PEG Ratio0.83
Price to Book (P/B)66.33
Price to Sales (P/S)18.75
P/FCF Ratio-74.16
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue20.51
Enterprise Value/Gross Profit21.10
Enterprise Value/Ebitda-72.34
Forecast
1Y Price Target
$50.14Price Target Upside36.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)2.41
Revenue Forecast (FY)$611.77M
Bulls Say, Bears Say
Bulls Say
Commercial AdoptionStrong prescription momentum with an expanding number of prescribers, rising patient starts, and high conversion rates indicates accelerating market adoption that should support ongoing sales growth and broader patient reach.
Profitability And Earnings LeverageVery high gross margins coupled with disciplined cost management and improving refill and adherence trends create attractive earnings leverage and a credible path toward sustained profitability that could draw investor interest.
Proprietary Technology DifferentiationThe PRINT particle-engineering technology enables more uniform, smaller particles and improved lung targeting compared with conventional dry powder inhalers, potentially sustaining a competitive advantage and enabling efficient dosing with better tolerability.
Bears Say
Competitive Device AnnouncementA partner's surprise announcement of a new inhaled device with unsupported claims has increased investor concern and could heighten competitive uncertainty despite the lack of comparative clinical evidence.
Funding And Cash RunwayCash resources appear limited relative to growth ambitions, creating potential funding risk that could lead to dilution or constrain investments in sales expansion and additional clinical programs.
Patent Litigation RiskOngoing patent litigation over a key patent represents a material overhang that could result in injunctions, label changes, or other restrictions and generate significant uncertainty for commercialization and investor sentiment.
Liquidia Technologies News
LQDA FAQ
What was Liquidia Technologies Inc’s price range in the past 12 months?
Liquidia Technologies Inc lowest stock price was $11.26 and its highest was $46.67 in the past 12 months.
What is Liquidia Technologies Inc’s market cap?
Liquidia Technologies Inc’s market cap is $3.24B.
When is Liquidia Technologies Inc’s upcoming earnings report date?
Liquidia Technologies Inc’s upcoming earnings report date is May 07, 2026 which is in 40 days.
How were Liquidia Technologies Inc’s earnings last quarter?
Liquidia Technologies Inc released its earnings results on Mar 05, 2026. The company reported $0.15 earnings per share for the quarter, missing the consensus estimate of $0.227 by -$0.077.
Is Liquidia Technologies Inc overvalued?
According to Wall Street analysts Liquidia Technologies Inc’s price is currently Undervalued.
Does Liquidia Technologies Inc pay dividends?
Liquidia Technologies Inc does not currently pay dividends.
What is Liquidia Technologies Inc’s EPS estimate?
Liquidia Technologies Inc’s EPS estimate is 0.37.
How many shares outstanding does Liquidia Technologies Inc have?
Liquidia Technologies Inc has 88,114,426 shares outstanding.
What happened to Liquidia Technologies Inc’s price movement after its last earnings report?
Liquidia Technologies Inc reported an EPS of $0.15 in its last earnings report, missing expectations of $0.227. Following the earnings report the stock price went up 0.407%.
Which hedge fund is a major shareholder of Liquidia Technologies Inc?
Currently, no hedge funds are holding shares in LQDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Liquidia Technologies Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$50.14 (36.36% Upside)
$50.14 (36.36% Upside)
Blogger Sentiment
Bullish
LQDA Sentiment 80%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 69.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $720.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.0%
Last 30 Days ▲ 7.0%
Last 30 Days ▲ 7.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
147.27%
12-Months-Change
Fundamentals
Return on Equity
-209.33%
Trailing 12-Months
Asset Growth
42.20%
Trailing 12-Months
Company Description
Liquidia Technologies Inc
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
LQDA Company Deck
LQDA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and clear evidence of rapid, profitable scale: robust Q4 sales growth, consecutive profitable quarters, meaningful cash generation, accelerating patient starts and prescriber adoption, and a pipeline of label- and market-expanding studies including a next-generation product. Risks highlighted include unresolved litigation, modest expected gross-to-net pressure as access expands, distributor inventory timing variability, and ongoing competitive entrants (oral agents and alternate inhaler formats). Management presented confident mitigation plans (expanded sales force, clinical transition studies, L606 development) and indicated operational cash funding for trials.View all LQDA earnings summariesLQDA Stock 12 Month Forecast
Average Price Target
$50.14
▲(36.36% Upside)
Technical Analysis
Ocular Therapeutix
―
Adaptive Biotechnologies
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Recursion Pharmaceuticals
―
Ownership Overview
21.80% Insiders
7.84% Mutual Funds
39.18% Other Institutional Investors
21.73% Public Companies and Individual Investors